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Abstract In systemic sclerosis (SSc), kidney damage is a
major clinical problem which can lead to a deleterious
outcome. Recently, in diabetes mellitus, early detection of
proteinuria and treatment with angiotensin-converting
enzyme (ACE) inhibitors has been shown to slow pro-
gression of kidney disease and to improve prognosis. In
this study, we investigated the spontaneous course of pro-
teinuria in SSc and the effects of ACE inhibitor therapy.
Proteinuria was determined in SSc patients with urine
protein electrophoresis. SSc patients with proteinuria
(n = 31) were followed over a median of 12 months. Of all
31 patients with pathologic urine protein electrophoresis
investigated in this study, 9 patients (29 %) had additional
microalbuminuria and 4 patients (12.9 %) showed
increased total urinary protein. ACE inhibitor treatment
was subsequently given to 23 patients. A total of 8 patients
remained untreated for various reasons. Proteinuria
resolved in 74 % of patients treated with ACE inhibitors,
whereas in the untreated group, remission was observed
only in 25 % (p = 0.014). Improvement of proteinuria was
predominantly achieved in patients with recently diagnosed
proteinuria and short disease duration. In patients with SSc
and proteinuria, initiation of ACE inhibitor therapy resulted
in a significant decrease in proteinuria.
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Introduction
Systemic sclerosis (SSc) is characterized by progressive
involvement of the vascular system resulting in impairment
of the affected organs. Involvement of kidney arteries
manifesting as renal crisis is a well-known, acute, life-
threatening complication. In autopsy studies, the incidence
of renal disease on a histopathological level was reported to
be 70–90 % [1], whereas Steen et al. [2] reported up to
32 % of renal involvement by clinical assessment of pro-
teinuria and renal function. In recent epidemiological
studies, the frequency of the most severe form of kidney
involvement, scleroderma renal crisis, is probably below
5 % [3–7, unpublished observation, Hunzelmann N.].
However, the impact of SSc-mediated chronic vascular
damage on glomerular integrity has not been examined in
detail yet. In diabetic patients, damage of the glomerular
capillaries leading to microalbuminuria and overt protein-
uria is a well-known phenomenon. Vascular kidney dam-
age can be detected at an early stage by increased
permeability for proteins passing the glomerular filtration
barrier [8, 9]. Various studies have dealt with the rela-
tionship between microalbuminuria and blood vessel
damage in different populations. These studies were able to
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show that microalbuminuria can be used as an early marker
for cardiovascular as well as non-cardiovascular mortality
[10–14]. Interestingly, in SSc, two recent epidemiological
studies identified proteinuria also as a risk factor for
increased mortality [15, 16].
A number of well-controlled studies have shown that
ACE inhibitors are capable of reducing proteinuria and of
stabilizing renal function in diabetic and non-diabetic
nephropathy [17–19]. Therefore, the aim of this study was
to investigate whether ACE inhibitor therapy improves
proteinuria in SSc patients.
Materials and methods
In this study, we investigated 31 clinically well-charac-
terized SSc patients with pathological urine microelectro-
phoresis. The study was regarded as exempt research
without requirement for informed consent as this was
review of existing data. Detailed patient characteristics are
shown in Table 1. Clinical data of patients were obtained
via a disease- and organ-specific questionnaire of the
German Network for Systemic Sclerosis (DNSS) as pre-
viously published [3]. All patients fulfilled the American
College of Rheumatology (ACR) criteria for SSc classifi-
cation and were categorized as diffuse, limited or overlap
syndrome as previously described [3]. Diabetes mellitus,
cardiac disease (palpitations, conduction disturbances and
diastolic dysfunction), arterial hypertension, cardiovascular
disease and pre-existing renal disease, defined as the
presence of renal insufficiency encompassing insufficiency
due to acute renal crisis (creatinine clearance \80 ml/
min 9 1.73 m2 of a 24-h urine collection, proteinuria or
albuminuria), were documented as relevant concomitant
diseases. Blood chemistry and serological tests included
the measurement of serum creatinine and autoantibody
levels. Six patients had hypertension, none of the patients
had diabetes mellitus, 6 had a smoking history, and 2 were
active smokers. Patients were followed over a median
period of 12 months (range 3–18 months).
Urine samples of a 24-h urine collection were tested for
albumin (Bromocresol green (BCG)-plus method), total
protein (benzethonium chloride method) and creatinine (j3-
Aminoghenazon (PAP) method). Pathologic albuminuria
was defined as C30 mg/24 h (male) or C20 mg/24 h
(female) or C25 mg/g urine creatinine (male) and C17 mg/
g urine creatinine (female). Pathological total proteinuria
was defined as followed: C300 mg/24 h or C200 mg/l or
C200 mg/g urine creatinine.
In addition, a more detailed qualitative examination of
excreted proteins was performed by urine microelectro-
phoresis (Fig. 1), which is about 709 more sensitive than
conventional dip stick analysis. This technique uses
undiluted urine samples, which are analysed by poly-
acrylamide gradient microgel electrophoresis, subsequent
Coomassie blue staining and densitometric scanning. It
allows the sharp separation and detection of urine proteins
within a range of 10–500 kD. The results of each patient
were graded either as normal, low-molecular-weight pro-
teinuria, intermediate-molecular-weight proteinuria or as
high-molecular-weight proteinuria as previously described
[20].
Patient data were analysed with reference to skin, organ
involvement and concomitant medication and their corre-
lation with total urine protein excretion and urine protein
composition.
Angiotensin-converting enzyme (ACE) inhibitors treat-
ment with ramipril 2.5 or 5 mg had been started in 23
patients as a preventive measure at the discretion of the
treating physician. Eight patients did not receive ACE
Table 1 Patient characteristics
Gender, age
Male 16.1 % (5/31)
Female 83.9 % (26/31)
Age (average/range in years) 62.09 % (41–74)
SSc subtypes
lcSSc 54.8 % (17/31)
dcSSc 35.5 % (11/31)
Overlap 9.7 % (3/31)
Antibody status
ACA 51.6 % (16/31)
Scl-70 29.0 % (9/31)
Organ involvement
Pulmonary arterial hypertension (PAH) 19.4 % (6/31)
Lung fibrosis 35.5 % (11/31)
Cardiac disease 19.4 % (6/31)
Cardiovascular disease 6.4 % (2/31)
GI 74.2 % (23/31)
Musculoskeletal 22.6 % (7/31)
Pre-existing renal disease 9.7 % (3/31)
Organ symptoms and laboratory parameters
mRSS \12 74.2 % (23/31)
mRSS C12 25.8 % (8/31)
Increased serum creatinine 3.2 % (1/31)
Increased urea 6.4 % (2/31)
ESR \21 mm/h 50.0 % (13/26)
ESR C21 mm/h 50.0 % (13/26)
Digital ulcers 25.8 % (8/31)
Hypertension 19.4 % (6/31)
Diabetes mellitus 0 % (0/31)
Systemic therapy
Steroids 29.0 % (9/31)
Immunosuppressive therapy 19.4 % (6/31)
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inhibitor treatment due to distinctive hypotension, known
incompatibilities or refusal by the patient. Consequently,
these patients could be used in the control group and were
shown to match in sex, age and ethnicity with the treated
group by Mann–Whitney U test (data not shown).
Statistical analysis was performed using SPSS (statisti-
cal package for social sciences; version 14) with Pearson’s
v-test, Fisher’s exact test for dichotomous variables and the
Mann–Whitney U test for nonparametric comparisons.
Results
All of the 31 patients investigated had abnormal urinary
low- and intermediate-molecular-weight protein excretion
as determined by microelectrophoresis. A typical patho-
logic intermediate-molecular-weight proteinuria as densi-
tometric printout is shown in Fig. 1. Additional
microalbuminuria was detected in 9 (29.0 %) of the 31
patients and further 4 (12.9 %) patients had an increased
amount of total urinary protein. In none of the patients,
microhematuria or increased excretion of immunoglobu-
lins, indicated by high-molecular-weight proteinuria, was
found. Organ involvement and concomitant medication
was similar to other patients in the DNSS registry as pre-
viously published [3].
Twenty-three of the 31 patients received ACE inhibitor
treatment. During an observation period with a median of
12 months (range 3–18 months), a normalization of pro-
teinuria was observed in 17 (73.9 %) of the 23 patients
treated. In the untreated control group, an improvement
was observed only in 2/8 patients (25 %, p = 0.014). The
duration of pathologic urinary microproteinuria in indi-
vidual patients is shown in Fig. 2.
Furthermore, in several patients with pathological
albuminuria and/or elevated total protein excretion, an
improvement was observed during ACE inhibitor therapy.
Two out of 7 patients with albuminuria and 2 of the ini-
tially 3 patients with elevated total protein excretion
showed a normalization of proteinuria associated with
ACE inhibitor therapy. None of the treated patients
developed hypotension, renal insufficiency or renal crisis.
Fig. 1 Urine
microelectrophoresis before and
after ACE inhibitor treatment A
typical scan profile of urinary
microelectrophoresis before
a and after c ACE inhibitor
treatment is shown (Pat. 5,
Fig. 2). The area under the
curves reflects total proteinuria.
Arrows indicate the position of
albumin, x-axis represents
molecular weight (kD) and y-
axis absorbance of the scanning
procedure. The numbers are
arbitrary units of the scanning
procedure. The respective
Coomassie blue stained gel is
shown in b and d
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The improvement of pathological protein excretion,
when correlated with clinical characteristics, was found to
be associated with a shorter disease duration, recently
diagnosed proteinuria, low inflammatory activity and lack
of additional immunosuppressive medication. However,
due to the low number of patients, these correlations did
not reach statistical significance.
Discussion
Renal involvement in SSc can occur either as a rare com-
plication of acute kidney failure, well known as sclero-
derma renal crisis, or as chronic progressive renal failure
with slow deterioration of kidney function. End-stage renal
disease in scleroderma is rare. In a recent study by Siva
et al. [21], the analysis of a large registry of ESRD patients
in Australia and New Zealand revealed a prevalence of
0.3 % for scleroderma patients. Median survival of these
patients was significantly shorter compared to non-sclero-
derma ESRD patients.
A central, early component of the vascular pathophysi-
ology in SSc is endothelial injury. Pronounced subendothe-
lial thickening with deposition of mucinous material is
observed in the interlobular arteries finally leading to a col-
lapse of tubuli due to postarteriolar ischaemia. It is assumed
that the loss of capillaries, which can be observed in affected
organs, is due to an increase in inflammation, angiostatic
factors and programmed cell death. In the kidney, endothe-
lial damage is known to accelerate glomerular leakage finally
leading to proteinuria.
Microalbuminuria is commonly used as an indicator of
early kidney damage, and the detection of increased albu-
min and/or total protein excretion is associated with poorer
renal and cardiovascular prognosis [12, 22–24]. Further-
more, albuminuria has been shown to be a marker for
systemic vasculopathy in patients with cardiovascular dis-
ease [9]. Therefore, proteinuria as an early preclinical
marker of renal pathology might also serve as a surrogate
marker for the severity of renal vascular pathology and for
prognosis in SSc [4]. This assumption is supported by
recent studies describing proteinuria as an independent
prognostic factor for survival in SSc [15, 16, 25]. Micro-
albuminuria is a hallmark of early diabetic nephropathy.
Although diabetic nephropathy is caused by a different
pathomechanism affecting primarily glomerular capillaries,
it is clear from large trials that renal outcome is improved
when treating patients with ACE inhibitors [26, 27]. The
Fig. 2 Duration of pathologic microproteinuria The x-axis indicates follow-up in months, the y-axis indicates individual patients (n = 23). The
grey bars indicate the duration of pathological microproteinuria. Arrows indicate time points of urine analysis
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presence of proteinuria alone is capable of increasing the
risk of a cardiovascular event to the same extent as a prior
myocardial infarction [28]. Therefore, lowering proteinuria
in SSc by ACE inhibitor treatment may have the same
beneficial effect on the incidence of cardiovascular events
in SSc patients.
In one of the few studies investigating chronic renal
involvement in SSc in more detail, Steen et al. [2] found
that 32 % of patients with diffuse SSc had abnormal renal
function and/or proteinuria. However, in their study, pro-
teinuria (defined as proteinuria(3 or 4?) on 2 occasions on
dipstick analysis or [250 mg/24 h) was mostly attributed
to the use of D-penicillamine or to other medical
comorbidities.
In 2008, Seiberlich et al. [20] performed a detailed
analysis of proteinuria in 80 patients with SSc with
abnormalities being present in 31.3 % of patients, con-
firming results of Steen et al. In addition to standard
methods of urinary protein determination, they used urine
microgradient gelelectrophoresis, which is among the most
sensitive methods for the detection of proteinuria. They
found a significant association between mixed proteinuria
and the diffuse type of systemic sclerosis, gastrointestinal
involvement and increased systolic blood pressure. A cor-
relation between albuminuria and increased systolic blood
pressure, as well as between albuminuria and longer illness
duration (4 year period) was also observed.
It is well established that the use of ACE inhibitors in
diabetes and hypertension leads to an improvement of
proteinuria, renal function and the risk of death and dialysis
[17–19]. In line with these studies, we observed a nor-
malization of urinary protein excretion in 74 % of SSc
patients treated by ACE inhibitors. It could also be dem-
onstrated that the normalization of microelectrophoresis
was accompanied by a decrease in albuminuria and total
urinary protein. The response to ACE inhibitor therapy was
less pronounced in patients with an elevated erythrocyte
sedimentation rate (ESR) and in those on immunosup-
pressive therapy reflecting a more intense inflammatory
phase of the disease. Of interest, in the recently published
large QUINS-Trial, no effect on 24-h total protein excre-
tion was found after prolonged therapy with Quinapril [29].
However, this may well be due to the fact that only a
comparison of total urinary protein excretion between the
verum and the placebo group was made (being on average
within normal limits in both groups).
The beneficial effect of ACE inhibition in this study
might be attributed to (1) the anti-proteinuric effect of the
ACE inhibitors by lowering intraglomerular pressure via
reduction of angiotensin II levels and (2) the inhibition of
the transforming growth factor-b (TGF-b) signalling cas-
cade, whereby ACE inhibitors possess additional direct
anti-fibrotic and anti-inflammatory potential [17, 30, 31].
This aspect may be of particular relevance for the treatment
for renal disease in SSc where TGF-b has been shown to
play a major pathogenetic role [32].
Previously, it had been stated that prophylactic use of
ACE inhibition in SSc may not protect against renal crisis
and may be even associated with worse outcomes [5, 6,
33]. On the other hand, the use of ACE inhibitors in
scleroderma renal crisis was reported to be beneficial [34].
In patients followed in our study, no adverse events asso-
ciated with ACE inhibitor therapy were observed.
In conclusion, this study shows for the first time that in
SSc patients, ACE inhibitor therapy can lead to a nor-
malization of urine protein excretion, a surrogate marker of
renal prognosis. A controlled trial will be required to
confirm these promising findings.
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